Regenexx, LLC
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Percutaneous delivery device and method for tendon-ligament-muscle repair (US 10,350,372) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Feb 4 to 25, 2027 · next Feb 4
- 1 fee due Apr 27, 2027The maintenance fee for Compositions and methods for cartilage repair (US 9,168,261) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Bone Marrow Adipose Portion Isolation Device and Methods (US 10,537,596) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Device and methods for platelet lysis or activation (US 11,903,970) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,700,583 | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,095,562 | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,871,199 | Compositions and methods to promote implantation and engrafment of stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,168,261 | Compositions and methods for cartilage repair In force · From the USPTO record | In force | From the USPTO record | |
| US 10,898,497 | Compositions and methods for cartilage repair In force · From the USPTO record | In force | From the USPTO record | |
| US 11,278,573 | Methods and compositions to facilitate repair of avascular tissue In force · From the USPTO record | In force | From the USPTO record | |
| US 9,113,950 | Therapeutic delivery device In force · From the USPTO record | In force | From the USPTO record | |
| US 12,233,188 | Bone Marrow Adipose Portion Isolation Device and Methods In force · Medium confidence | In force | Medium confidence | |
| US 10,537,596 | Bone Marrow Adipose Portion Isolation Device and Methods In force · Medium confidence | In force | Medium confidence | |
| US 11,903,970 | Device and methods for platelet lysis or activation In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 3 no status recorded